UNSPSC 51281719: Lenampicillin hydrochloride

This classification denotes a penicillin antibiotic C21H23N3O7S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6U90E2WB40, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2r)-2-amino-2-phenylacetyl)amino)-3,3-dimethyl-7-oxo-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, hydrochloride (1:1), (2s,5r,6r)-, but more generally known as lenampicillin hydrochloride, which bears US NIH Compound Identifier 6917773.

UNSPSC 51281719 Lenampicillin hydrochloride is a Commodity code, but the source shows no recent state or local procurement activity for this specific pharmaceutical product. The most recent opportunities tagged under this code involve naloxone, medical and first aid supplies, and generic multi-source pharmaceuticals and OTC products—none of which target lenampicillin hydrochloride directly. The mismatch between the code's nominal scope and the actual solicitations posted suggests that state and local procurement systems are applying this code inconsistently or that it serves as a placeholder for broader pharmaceutical procurement categories that encompass multiple drug products.

Issuing bodies across the recent opportunities include county health systems (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), municipal fire departments and purchasing offices (City of Tampa), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities in Minnesota and Oregon). The representative opportunities include Seminole County's IFB for naloxone and drug deactivation systems (response deadline July 26, 2023), the City of Tampa's IFB for medical and first aid supplies for its Fire Department Rescue Division with an estimated contract value of $700,000.00 (due March 13, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026). The Texas HHS Commission posted an RFI on direct-to-manufacturer prescription programs (April 3, 2026) to explore procurement models outside traditional pharmacy benefit managers and group purchasing organizations. Geographic activity centers on Florida, Texas, and the Upper Midwest, with multi-state participation through cooperative purchasing vehicles. Given the absence of lenampicillin-specific solicitations and the code's apparent misapplication in recent state and local postings, this code warrants monitoring for actual demand signals rather than immediate pursuit.